ClinicalTrials.Veeva

Menu
A

Advanced Respiratory and Sleep Medicine, PLLC | Huntersville, NC

Research site

Site insights

Top conditions

Top treatments

FT218
Mazindol
AD109
SAR440340
Aroxybutynin
XYWAV
BI 1291583
Verekitug
Astegolimab
High-Sodium Oxybate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Felix Kurniawan

Verified by this site

Active trials

9 of 19 total trials

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this...

Active, not recruiting
Bronchiectasis
Drug: Placebo
Drug: Itepekimab (SAR440340)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab (SAR440340)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Active, not recruiting
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive...

Active, not recruiting
Obstructive Sleep Apnea
Drug: Acetazolamide
Drug: IHL-42X Low Dose

This is a double-blind, placebo-controlled, randomized withdrawal, multicenter study of the efficacy and safety of FT218. FT218 drug product is a onc...

Enrolling
Idiopathic Hypersomnia
Other: Placebo
Drug: FT218

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and...

Enrolling
Bronchiectasis
Drug: Placebo matching BI 1291583
Drug: BI 1291583

Trial sponsors

Sanofi logo
Apnimed logo
A
B
Jazz Pharmaceuticals logo
N
Axsome Therapeutics logo
Boehringer Ingelheim logo
I
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems